Rep. Dwight Evans discloses trade(s) in AMT, CVS, INTC, PWR, TMO
Dwight Evans (PA03) disclosed 5 transactions, traded Nov 21 – May 11: 0 purchases and 5 sales.
| Traded | Ticker | Company | Action | Amount | Owner |
|---|---|---|---|---|---|
| May 11 | AMT | American Tower Corporation | Sell | $1,001 - $15,000 | Self |
| May 7 | INTC | PERSHING LLC Intel Corporation | Sell (partial) | $1,001 - $15,000 | Self |
| May 7 | PWR | CETERA Quanta Services, Inc. | Sell (partial) | $1,001 - $15,000 | Self |
| May 7 | TMO | CETERA Thermo Fisher Scientific Inc | Sell (partial) | $1,001 - $15,000 | Self |
| Nov 21 | CVS | CETERA 2000152177 CVS Health Corporation | Sell (partial) | $1,001 - $15,000 | Self |
ORIGINAL FILING ↗ALL FILINGS BY DWIGHT EVANS →CONGRESS TRADES DASHBOARD →
Amounts are the ranges members report. Rows are read automatically from the filing; a trade split across a page break can be missed, so the original filing is the full record.
What This Means
A U.S. House member has filed required disclosures of stock transactions in five companies spanning healthcare, semiconductors, utilities, and real estate. Congressional stock trading disclosures are public record and tracked by markets observers and governance watchdogs as a window into insider positioning and potential conflicts of interest, though disclosure alone does not indicate impropriety or predict market moves.
Sources (1)
Every claim below links directly to the original reporting it was drawn from. Penblock synthesizes and cross-references these sources — it doesn't originate the reporting.
- Hon. Dwight EvansSep 28, 2026View the original filing at the House Clerk ↗
How This Could Play Out
First assessed Sep 28
Resolved
LIKELYThe disclosure remains a routine filing with no follow-up scrutiny or legislative action tied to these holdings, treating it as standard transparency compliance with minimal market relevance.
Status quo
LIKELYThese trades continue to circulate in congressional trading databases without triggering media attention, activist pressure, or regulatory review, leaving sector and stock-specific sentiment unaffected by the disclosure itself.
Worsens
UNLIKELYIf subsequent reporting or investigation reveals a pattern of trades preceding legislative action on healthcare, semiconductors, or infrastructure—or conflicts between Evans' committee assignments and his holdings—it could amplify scrutiny of congressional trading practices and create reputational pressure on affected sectors.
SPONSORED
More on Congressional Stock Trading
- Rep. James A. Himes files a Periodic Transaction ReportOct 20
- Rep. Jonathan Jackson discloses trade(s) in DDOG, EL, GH, TYG, VSATOct 19
- Rep. Michael Rulli discloses trade(s) in GOOG, WSBCOct 19
- Attorneys for Ilhan Omar seek return of items taken during home searchOct 17
- Rep. Laurel Lee discloses trade(s) in BAC, NOKBFOct 16
- Rep. Scott H. Peters files a Periodic Transaction ReportOct 15
Get the market digest by email
One email each morning: yesterday's key story and what it means for markets. Free.